Arvinas (NASDAQ:ARVN) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Arvinas (NASDAQ:ARVN) from a sell rating to a hold rating in a research note issued to investors on Monday morning, Zacks.com reports.
According to Zacks, “Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. “
Several other research firms have also weighed in on ARVN. Wedbush initiated coverage on Arvinas in a report on Tuesday, September 24th. They set an outperform rating and a $38.00 target price on the stock. Cantor Fitzgerald initiated coverage on Arvinas in a report on Monday, August 5th. They set an overweight rating ...